Increased Diacylglycerols Characterize Hepatic Lipid Changes in Progression of Human Nonalcoholic Fatty Liver Disease; Comparison to a Murine Model
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS: The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepatitis (NASH), and progression to cirrhosis. While differences in liver lipids between disease states have been reported, precise composition of phospholipids and diacylglycerols (DAG) at a lipid species level has not been previously described. The goal of this study was to characterize changes in lipid species through progression of human NAFLD using advanced lipidomic technology and compare this with a murine model of early and advanced NAFLD. METHODS: Utilizing mass spectrometry lipidomics, over 250 phospholipid and diacylglycerol species (DAGs) were identified in normal and diseased human and murine liver extracts. RESULTS: Significant differences between phospholipid composition of normal and diseased livers were demonstrated, notably among DAG species, consistent with previous reports that DAG transferases are involved in the progression of NAFLD and liver fibrosis. In addition, a novel phospholipid species (ether linked phosphatidylinositol) was identified in human cirrhotic liver extracts. CONCLUSIONS: Using parallel lipidomics analysis of murine and human liver tissues it was determined that mice maintained on a high-fat diet provide a reproducible model of NAFLD in regards to specificity of lipid species in the liver. These studies demonstrated that novel lipid species may serve as markers of advanced liver disease and importantly, marked increases in DAG species are a hallmark of NAFLD. Elevated DAGs may contribute to altered triglyceride, phosphatidylcholine (PC), and phosphatidylethanolamine (PE) levels characteristic of the disease and specific DAG species might be important lipid signaling molecules in the progression of NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285 · cited 1×
“Lipid accumulation in hepatocytes makes them more susceptible to injury by oxidative stress and inflammatory cytokines, whose production in the liver is triggered by the lipid peroxidation products [28,29].”
BackgroundEffects of the obese Gene Product on Body Weight Regulation in ob / ob Mice
Pelleymounter, M. A., Cullen, M. J., Baker, M. B., Hecht, R., Winters, D., Boone, T., & Collins, F. (1995) · Science · doi:10.1126/science.7624776 · Cited by 4,017 · cited 1×
“Multiple animal models have been developed to address metabolism, signaling pathways, and genetic variance that affect the development of steatosis and steatohepatitis [7,8].”
BackgroundProtein kinase C and lipid signaling for sustained cellular responses
Nishizuka, Y. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.7.7737456 · Cited by 2,499
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research
Anstee, Q. M., & Goldin, R. D. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2006.00465.x · Cited by 714
The plasma lipidomic signature of nonalcoholic steatohepatitis
Puri, P., Wiest, M. M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H., Contos, M. J., Sterling, R. K., Fuchs, M., Zhou, H., et al. (2009) · Hepatology · doi:10.1002/hep.23229 · Cited by 655 · cited 1×
“The observed increase in plasmalogen PC and PE in the diseased samples compared to normal could reflect an accumulation in the liver in contrast to the decreased levels of plasmalogen lipids in plasma from NASH and NAFLD cases as a signature of peroxisomal dysfunction [25].”
Dissociation of Hepatic Steatosis and Insulin Resistance in Mice Overexpressing DGAT in the Liver
Monetti, M., Levin, M. C., Watt, M. J., Sajan, M. P., Marmor, S., Hubbard, B. K., Stevens, R. D., Bain, J. R., Newgard, C. B., Farese, R. V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.005 · Cited by 511 · cited 1×
“TAG synthesis (largely regulated by diacylglycerol acyl transferase (DGAT)) protects hepatocytes from free fatty acid (FFA) accumulation [30], thus making its precursor DAG an equally important player.”
Background
Cited by
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
Saponaro, C., Gaggini, M., Carli, F., & Gastaldelli, A. (2015) · Nutrients · doi:10.3390/nu7115475 · Cited by 529
Mardinoglu, A., Agren, R., Kampf, C., Asplund, A., Uhlen, M., & Nielsen, J. (2014) · Nature Communications · doi:10.1038/ncomms4083 · Cited by 519
Leamy, A. K., Egnatchik, R. A., & Young, J. D. (2013) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.10.004 · Cited by 412
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p056002 · Cited by 372
Self-citationAzzu, V., Vacca, M., Virtue, S., Allison, M., & Vidal-Puig, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.054 · Cited by 369
Dietary carbohydrates and fats in nonalcoholic fatty liver disease
Yki-Järvinen, H., Luukkonen, P. K., Hodson, L., & Moore, J. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00472-y · Cited by 294
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
Masuoka, H. C., & Chalasani, N. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12016 · Cited by 283
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus
Xourafa, G., Korbmacher, M., & Roden, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00898-1 · Cited by 274
“Moreover, people with NAFLD exhibit increased postprandial hepatic secretion of endogenous diacylglycerols 240 , which probably contribute to altered triacylglycerol, phosphatidylcholine and phosphatidylethanolamine levels 241 and/or to altered hepatic insulin signalling 242 .”
BackgroundLipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis
Hirsova, P., Ibrabim, S. H., Gores, G. J., & Malhi, H. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r066357 · Cited by 270
“Liver lipidomic analyses in NAFLD have demonstrated increased diacylglycerol, free cholesterol, and lysophosphatidylcholine (LPC), in addition to the morphologically obvious triglyceride (Table 1) (3-7).”
Cellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252
“…different types of lipid species have been shown to be associated with NAFLD such as saturated free fatty acids (FFA), diacylglycerols, ceramides, lysophosphatidylcholine, eicosanoids and free cholesterol (Feldstein et al., 2003; Caballero et al., 2009; Gorden et al., 2011; Luukkonen et al., 2016).”
BackgroundDiabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo
Williams, K. H., Shackel, N. A., Gorrell, M. D., McLennan, S. V., & Twigg, S. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1009 · Cited by 233
Farrell, G. C., Haczeyni, F., & Chitturi, S. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_3 · Cited by 178
Zhou, M., Learned, R. M., Rossi, S. J., DePaoli, A. M., Tian, H., & Ling, L. (2017) · Hepatology Communications · doi:10.1002/hep4.1108 · Cited by 152
Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity
Anjani, K., Lhomme, M., Sokolovska, N., Poitou, C., Aron-Wisnewsky, J., Bouillot, J.-L., Lesnik, P., Bedossa, P., Kontush, A., Clement, K., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.002 · Cited by 106
“[25] also observed increased DAG in steatotic compared to normal liver, but reported mostly unchanged; Glycerophosphocholines (PC), Glycerophosphoethanolamines (PE) and Glycerophosphoinositols (PI).”
BackgroundGPCR activation of Ras and PI3Kγ in neutrophils depends on PLCβ2/β3 and the RasGEF RasGRP4
Suire, S., Lécureuil, C., Anderson, K. E., Damoulakis, G., Niewczas, I., Davidson, K., Guillou, H., Pan, D., Clark, J., Hawkins, P. T., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.167 · Cited by 77
“Previously, this has been achieved by derivatization and HPLC (Pettitt and Wakelam, 1993) or by lipidomic/mass spectrometry-based methods (Gorden et al , 2011), but in both cases demands significant input material.”
A human liver chimeric mouse model for non-alcoholic fatty liver disease
Bissig-Choisat, B., Alves-Bezerra, M., Zorman, B., Ochsner, S. A., Barzi, M., Legras, X., Yang, D., Borowiak, M., Dean, A. M., York, R. B., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100281 · Cited by 49
Hepatic Fatty Acid Balance and Hepatic Fat Content in Humans With Severe Obesity
Lytle, K. A., Bush, N. C., Triay, J. M., Kellogg, T. A., Kendrick, M. L., Swain, J. M., Gathaiya, N. W., Hames, K. C., & Jensen, M. D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00875 · Cited by 35
Metadata
- Authors
- Gorden, D. L., Ivanova, P. T., Myers, D. S., McIntyre, J. O., VanSaun, M. N., Wright, J. K., Matrisian, L. M., & Brown, H. A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-08-09
- Volume
- 6
- Issue
- 8
- Pages
- e22775
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2014622450
- Cited by
- 155
- References
- 7
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.